Short communication: Dynamic constraints on the second phase compartment of HIV-infected cells

AIDS Research and Human Retroviruses

Volumn 27, Issue 7, 2011, Pages 759-761

  Spivak, Adam M ^a   Rabi, S Alireza ^a   McMahon, Moira A ^a   Shan, Liang ^a   Sedaghat, Ahmad R ^a,d   Wilke, Claus O ^b   Siliciano, Robert F ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; RALTEGRAVIR;

ARTICLE; CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; VIREMIA;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; VIRUS LATENCY;

EID: 79959855650     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0199     Document Type: Article

References (19)

1. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M:Rapid turnoverofplasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586. (Pubitemid 26097216)
4. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191. (Pubitemid 27209434)
5. Wodarz D and Nowak MA: Mathematical models of HIV pathogenesis and treatment. Bioessays 2002;24:1178-1187. (Pubitemid 35464947)
6. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, and Siliciano RF: Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008; 105:4832-4837. (Pubitemid 351753832)
7. Sedaghat AR, Siliciano RF, and Wilke CO: Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antiviral Ther 2009;14:263-271.
8. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratana-suwan W, Kovacs C, et al.: Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125-133. (Pubitemid 47482607)
9. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, et al.: Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007;21:2315-2321. (Pubitemid 350287458)
10. Zhou Y, Zhang H, Siliciano JD, and Siliciano RF: Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4\+ T cells. J Virol 2005;79:2199-2210. (Pubitemid 40204577)
11. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al.: Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008;14:762-766. (Pubitemid 351951518)
12. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al.: Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active anti-retroviral therapy. Proc Natl Acad Sci USA 2009;106:9403-9408.
13. Arfi V, Riviere L, Jarrosson-Wuilleme L, Goujon C, Rigal D, Darlix JL, et al.: Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J Virol 2008;82:6557-6565. (Pubitemid 351875132)
14. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, and Chen IS: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
15. Bukrinsky MI, Stanwick TL, Dempsey MP, and Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427. (Pubitemid 21917358)
16. Spina CA, Guatelli JC, and Richman DD: Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995;69:2977-2988.
17. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, et al.: Biphasic decay of latently infected CD4\+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000;182:1636-1642.
18. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, et al.: Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 1992;89:6580-6584.
19. Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, et al.: Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004;78:1718-1729. (Pubitemid 38176704)